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SUMMARY
Setting—Initial cost-effectiveness evaluations of Xpert MTB/RIF (Xpert) for tuberculosis (TB)
diagnosis have not fully accounted for realities of implementation in peripheral settings.
Objective—We evaluated costs and diagnostic outcomes of Xpert testing implemented at various
healthcare levels in Uganda.
Design—We collected empirical cost data from five health centers utilizing Xpert for TB
diagnosis, employing an ingredients approach. We reviewed laboratory and patient records to
assess outcomes in these sites and ten sites without Xpert. We also estimated incremental cost-
effectiveness of Xpert testing; our primary outcome was incremental cost of Xpert testing per
newly detected TB case.
Results—The mean unit cost of an Xpert test was US$21 based on a mean monthly volume of 54
tests per site, though unit cost varied widely (US$16–58) and was primarily determined by testing
volume. Total diagnostic costs were 2.4-fold higher in Xpert clinics compared to non-Xpert
clinics, though Xpert only increased diagnoses by 12%. Diagnostic costs of Xpert averaged US
$119 per newly detected TB case but were as high as US$885 in the lowest-volume center.
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Conclusion—Xpert testing can detect TB cases at reasonable cost but may double diagnostic
budgets for relatively small gains, with cost-effectiveness deteriorating with lower testing
volumes.
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INTRODUCTION
Tuberculosis (TB) is the leading single-agent infectious cause of death globally, responsible
for 1.5 million deaths in 2014.1 An estimated 3.6 million cases go unreported every year;
reaching this “missing 3 million” is among the highest priorities for global TB control.1 In
2010, the World Health Organization endorsed Xpert MTB/RIF (Xpert), a molecular TB
diagnostic test that can provide results in two hours with minimal human resource
requirements, higher sensitivity than sputum smear microscopy, and the ability to identify
multi-drug resistant (MDR-) TB based on detected resistance to rifampin.2,3 Scale-up has
been rapid, with more than 10 million cartridges procured under concessional pricing in over
100 countries through 2014.4,5 However, while sputum smear microscopy costs $1–$3 per
test in most high-burden countries,6 Xpert has been estimated to cost between $15 and $50
per test.7–11 Thus, a key question is whether the improved accuracy of Xpert is worth the
additional cost.
Initial economic evaluations suggested that Xpert is cost-effective, though estimations of
incremental cost-effectiveness vary.7,8,11–13 These earlier modeling studies largely assumed
efficiently functioning laboratories that served as initial sites of Xpert scale-up. Over time,
however, the focus of Xpert implementation has shifted to district and subdistrict
levels,14–16 where the cost of Xpert may be substantially higher because of lower testing
volumes or additional costs associated with transport and installation.17 Previous work in
South Africa has suggested that point-of-treatment placement of Xpert could increase Xpert
testing cost by 50% or more;9 whether that additional cost, as well as the linkage between
such additional cost and the potential for Xpert to improve diagnostic outcomes, generalizes
to high-burden low-income settings remains uncertain.
Recent evidence has also suggested that Xpert, as implemented in African primary-care
settings, may not improve treatment, morbidity, or mortality outcomes as much as initially
expected.18–20 Xpert effectiveness may be further reduced in non-trial settings because of
equipment failure, uncertain electrical supply, ongoing calibration requirements, and
unanticipated patterns of use (e.g., treatment monitoring).9,17 It is thus important to collect
data on both costs and outcomes of Xpert implementation in peripheral settings, particularly
in high-burden, low-income countries where funding gaps suggest that affordability of Xpert
remains a key question.1 Here, we report on the costs of Xpert testing and corresponding
diagnostic outcomes across regional hospitals, district hospitals and sub-district health
centers in Uganda, a typical sub-Saharan African setting with high rates of TB and HIV/TB
and the site of prior studies of Xpert’s effectiveness21 and cost-effectiveness.11
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METHODS
Ethical considerations
This study received approval from institutional review boards at Makerere University
College of Health Sciences in Kampala, Uganda, and Johns Hopkins Bloomberg School of
Public Health in Baltimore, MD, USA.
Overview
We nested this evaluation of Xpert costs and TB diagnoses into a larger observational study
of implementing TB diagnostic algorithms in Uganda.22 Data were collected at 18 rural and
urban health facilities from 2012–2014, selected to be representative of both geography and
health system level: one national referral center (not included in this analysis), four regional
referral centers, nine district hospitals, and four sub-district health centers. Xpert had been
implemented in seven sites (plus the national referral center) at the time of evaluation,
whereas the remaining 10 sites had laboratories capable of performing sputum smear
microscopy. These 10 sites provided Xpert testing only as an offsite referral test from
another health center (and only rarely). Here we compared five sites where Xpert was
implemented (excluding two sites that served as referral centers) against the ten sites without
Xpert.
Our primary aim was to measure costs and diagnostic outcomes related to Xpert testing as
actually implemented in various levels of the Ugandan healthcare system in order to explore
the primary drivers of Xpert cost-effectiveness in such settings. Because we did not measure
the costs or outcomes of treatment, we did not attempt to estimate cost-effectiveness in
terms of cost per disability-adjusted life year (DALY) averted, but rather used cost per
diagnostic outcome (diagnosis of TB or rifampin-resistant TB) as a more proximal measure
for exploring the key drivers of cost-effectiveness in these settings.
Empiric costing
We estimated diagnostic costs from the health system perspective using a unit-based
“ingredients” approach. This method identifies and values all inputs required to perform
diagnostic testing in order to develop a unit cost for each test. At five sites with Xpert
implementation (two regional hospitals, one district hospital, and two sub-district [Level IV]
health centers), we collected costs of overhead, building space, equipment, staff, reagents,
and consumables related to Xpert testing and smear microscopy. We used a combination of
laboratory personnel interviews, budgetary documentation reviews, procurement guides, and
publically available product information. Overhead costs were allocated based on
proportional space required for TB testing and percentage of staff time devoted to TB
testing, as appropriate. To determine allocation of costs of shared resources between Xpert
testing and non-Xpert testing, we directly observed time and motion of laboratory
procedures at each site. For smear microscopy, we assumed an algorithm consisting of two
smears per patient. Costs and diagnostic outcomes of TB culture (performed only rarely in
these sites) were excluded.
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We assumed that one person would require training in Xpert use per site per year, and that
Xpert cartridge procurement and transportation would equal 10% of the US$9.97 cartridge
list price, based on consultation with experts in Uganda. Cost of shipping the GeneXpert
four-cartridge system was incorporated as a 10.9% markup of the ex-works list price.23
Annual maintenance of GeneXpert was based on annual warranty cost24 with a 5 year
expected lifetime, whereas we assumed annual maintenance costs of all other durable
equipment and building space to be 5% of total cost each year given assumed expected
lifetime of 30 years. All future costs were discounted at 3% per year.25 Costs were measured
in 2014 currency and converted to US dollars using published exchange rates.
Estimation of diagnoses made
We reviewed 12 months of TB laboratory records, including electronic Xpert instrument
logs and laboratory specimen registers, for Xpert testing volume and results of Xpert and
smear microscopy at each site as reported previously.22 Laboratory results and treatment
data for 100 consecutive patients who provided sputum samples were also abstracted at each
site in order to establish linkages between test results and treatment initiation. In order not to
underestimate the cost-effectiveness of Xpert in diagnosing smear-negative TB, we assumed
that Xpert tests run without a specific reason recorded were performed for the purpose of
diagnosing TB over other reasons (e.g., treatment monitoring).
Analysis of outcomes
Primary cost outcomes were the cost per Xpert test performed and the incremental cost of
diagnosis of a new TB case due to Xpert. Our primary effectiveness outcome was the
number of positive Xpert tests performed on individuals without known pre-existing TB. A
secondary effectiveness outcome was the number of Xpert tests indicating rifampin
resistance among individuals not previously documented as having MDR-TB. For each
Xpert site, we calculated the mean monthly cost of Xpert testing, mean number of
incremental TB diagnoses, and thus the cost per diagnosis made. Finally, we compared
mean facility-level estimates of monthly diagnostic costs and number of individuals started
on TB treatment between sites with and without Xpert.
Uncertainty analysis
We directly measured costs and diagnostic outcomes, and therefore did not need to use
parameter values from literature. Nevertheless, our sample size of five Xpert sites still leads
to uncertainty in our estimates as a reflection of other similar Ugandan clinics. To capture
this uncertainty, we adopted a probabilistic approach in which we drew 10,000 samples of
testing volume, Xpert unit cost (as a function of testing volume), and number of newly
diagnosed TB and MDR-TB cases (as a function of testing volume). Testing volume was
modeled as a gamma distribution to reflect the zero bound and right skew observed in our
data. In each simulation, we calculated the diagnostic cost per Xpert test positive for TB and
diagnostic cost per Xpert test positive for rifampin resistance. We also compared the cost-
effectiveness of TB testing in simulated sets of nine small-volume facilities (<20 tests per
month) against single large-volume facilities (> 20 tests per month; mean nine times larger
than small-volume facilities).
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RESULTS
Unit cost of Xpert
Across the five sites evaluated, the mean unit cost of Xpert was US$21 based on an
observed mean monthly volume of 54 tests per site (Figure 1). Reagents (including the Xpert
cartridge) and equipment comprised 93% of this unit cost, which varied from US$16 to US
$58 across sites. The primary driver of this variation was testing volume, which tended to be
higher in regional and district hospitals and lower in sub-district health centers. If all five
facilities operated under their lowest-volume conditions observed over the 12-month
periods, the estimated mean unit cost would rise from US$21 to US$65 (Table 1).
Xpert diagnostic costs and outcomes
The estimated monthly incremental diagnostic cost of Xpert testing at each site ranged from
US$590–US$2098 (Table 2). Regional and district-level hospitals had higher total costs for
the overall Xpert testing program per month due to larger volumes of Xpert testing. On
average, of the 54 Xpert tests per site per month, 9.6 were positive for TB and 0.5 indicated
rifampin resistance, though variation across sites was substantial. The diagnostic cost per
positive Xpert test on patients not known to have TB averaged US$119 (range US$80–885),
whereas the diagnostic cost per positive test for rifampin resistance among those without
known pre-existing resistance averaged US$1383 (range US$896–7081), reflecting the
smaller number of rifampin-resistant cases diagnosed. Cost per positive diagnosis was
highest in sites with lowest volumes of testing.
Figure 2 presents the estimated incremental costs and diagnoses due to Xpert by comparing
costs, number of diagnoses, and number started on treatment at Xpert versus non-Xpert
sites. The total cost of TB diagnosis per month averaged US$1679 per Xpert site. Total TB
diagnostic costs were 2.4-fold higher in clinics with Xpert testing compared to those without
(US$702, based on our empiric estimate of US$1.41 per sputum smear). However, Xpert
resulted in an estimated 5.3 incremental diagnoses per site per month, an incremental yield
of only 12%. While treatment initiations were 31% higher in Xpert versus non-Xpert sites,
rates of treatment initiation after diagnostic testing at Xpert and non-Xpert sites were similar
at 87% and 89%, respectively.
Uncertainty analysis
Figure 3 presents the distribution of costs per Xpert test positive for TB and per test positive
for rifampin resistance across 10,000 simulated months of testing. The median cost per
Xpert test positive for TB was US$106. Among simulations in which Xpert testing volume
was less than 20 per month per site, this median diagnostic cost was $918, versus $138
among simulations in which monthly testing volume was at least 20.
DISCUSSION
This economic investigation of Xpert implementation across regional, district, and sub-
district health centers in Uganda suggests that costs and impact of Xpert testing vary widely
across sites and levels of the health system, with a strong dependence on testing volume. For
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example, the diagnostic cost per positive Xpert test ranged from US$80 in the highest-
volume site to US$885 in the lowest-volume site. Xpert testing accounted for more than
60% of all diagnostic costs but was responsible for no more than 12% of new TB diagnoses.
As Xpert is increasingly implemented in lower-volume settings, it may become less cost-
effective.
Consistent with prior studies performed under conditions of greater resource
availability,19,26 we found that implementation of Xpert in Uganda (a country with fewer
resources and outside a trial setting) led to few incremental TB diagnoses relative to the
current standard based on sputum smear. We augment this understanding by correlating
diagnostic outcomes with the incremental cost of Xpert, which constituted over 60% of
diagnostic costs in sites utilizing Xpert. In our uncertainty analysis simulations, the median
cost per new TB case detected was US$106; however, this increased when considering
Xpert implementation in sites with low testing volume. These findings may help inform
decision-makers about the appropriateness of Xpert deployment in different settings.
Prior analyses have estimated the mean unit cost of Xpert to vary within US$20–$30
depending on country deployed,11 while others have also noted that testing volume is an
important contributor to cost variations.9,10 Our analysis builds on this by describing the
degree of variability that could be observed even within the same health system. This
research suggests that there is likely a threshold testing volume – and thus, a threshold level
of healthcare system – at which Xpert should be implemented. Such thresholds may raise
concerns about trade-offs between equity and efficiency in peripheral settings, especially as
some apparent cost savings from a more centralized referral system may in fact represent
costs shifted away from the health system and instead toward patients who would have to
travel further, wait longer for results, and delay treatment initiation. Cost-effectiveness of
Xpert testing at lower-volume centers could potentially be improved with increased volume
of patients referred for testing, such as through facility-based screening and other intensified
case-finding initiatives.27,28 Alternatively, referral networks could be further developed to
deliver sputum specimens efficiently to more centralized sites,29,30 an approach which must
consider quality of available transport networks and potential for pre-treatment loss to
follow-up while awaiting results. Novel lower-cost platforms for Xpert testing (e.g., Xpert
Omni,31 Alere q32) may also aid in cost-effective decentralization of testing. Future research
should evaluate the appropriate healthcare level for Xpert implementation in different
economic and epidemiological settings, investigate the economic impact of alternative
approaches in peripheral settings, and evaluate trade-offs between patient costs and
healthcare system costs when placing Xpert centrally versus peripherally.
Our study has several limitations. First, we only included costs of Xpert and sputum smear
microscopy in estimating diagnostic costs, excluding ancillary evaluation (e.g., chest X-ray,
antibiotic trials) costs. As a result, we likely underestimate the true diagnostic program cost
at both Xpert and non-Xpert sites. Second, we took as our primary effectiveness outcome
the observed number of positive Xpert tests not performed on those with known TB, which
may overestimate the incremental value of Xpert. Third, HIV status was not reliably logged
in patient records. We were therefore unable to evaluate the differential costs and impact on
diagnoses from Xpert testing within this important sub-group.33 Finally, we measured costs
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from the healthcare perspective and did not incorporate patient costs. Including patient costs
would increase overall estimates of diagnostic and treatment costs, though the incremental
cost due to Xpert might differ according to diagnostic algorithm (e.g., whether testing is
same-day).
In summary, this analysis demonstrates that Xpert diagnostic costs and impact on TB and
MDR-TB diagnoses made can vary widely at different levels of the same healthcare system,
with cost-effectiveness deteriorating substantially in low-volume settings. As Xpert is scaled
up to sites with increasingly lower testing volumes, more attention must be paid to proper
placement within the healthcare system and the development of alternative strategies to
make peripheral implementation more cost-effective. Future policy guidance for Xpert and
emerging TB diagnostic tests34 should carefully consider the economic realities of testing in
peripheral settings when recommending implementation strategies.
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Figure 1. Unit cost of Xpert test by input type at each site
The height of each column (in bold above each column) represents the mean unit cost of
Xpert at each of five sites in Uganda; the corresponding observed monthly Xpert volume is
indicated in circles below each column. Different shades within each bar represent
components of the unit cost. Note that Kayunga, as a district hospital, is at a lower level of
the Uganda healthcare system than Arua and Fort Portal regional hospitals, but had a greater
volume of tests. *The cost of reagents includes the Xpert cartridge. **Includes costs of
overheads, building space, staff time, and consumables. ***Because time-motion data for
Xpert testing was not collected at Arua, allocation of resources not directly related to Xpert
(i.e., all but GeneXpert system and Xpert cartridge) was based on time-motion studies in
Fort Portal; these resources accounted for 9% of costs per Xpert test in Fort Portal.
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Figure 2. Incremental costs and associated diagnostic and treatment impact of Xpert
implementation
The left graph shows costs of diagnosis from the healthcare setting in sites without and with
on-site Xpert testing, while the right graph shows corresponding outcomes: the number of
cases diagnosed and number of cases started on treatment. Incremental newly diagnosed
cases due to Xpert (in light blue) were estimated by applying the observed proportion of
newly diagnosed cases with a preceding positive Xpert result (Table 2) to the mean number
of new TB diagnoses diagnosed by Xpert per month in sites with on-site Xpert testing
available. The remaining TB cases at Xpert sites were either detected by smear microscopy
or started on treatment before a positive Xpert result.
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Figure 3. Distribution of cost per positive Xpert test across 10,000 probabilistic simulations
Boxplots represent the distributions of cost-effectiveness estimates in probabilistic
sensitivity analyses considering the cost per Xpert test positive for TB (left panel) or
rifampin resistance (right panel). Boxes represent interquartile ranges; whiskers represent
the 5th and 95th percentiles (not including simulations for which Xpert did not increase the
number of positive tests [17% of simulations] or lead to any individuals being diagnosed
with rifampin resistance [13% of simulations]).
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Table 1
Unit cost of Xpert test by monthly volume
Weighted mean cost of Xpert test (2014 US$)*
Input Type At minimum monthly volume At median monthly volume At maximum monthly volume
Overhead 0.03 0.03 0.03
Building space 1.79 1.35 0.15
Equipment 50.94 9.44 4.33
Staff 0.40 0.40 0.37
Reagents 10.97 10.98 10.99
Consumables 0.67 0.72 0.75
TOTAL 64.80 22.92 16.62
*
Calculated by adding variable monthly costs of building space and equipment with constant monthly costs of all other input types as would be
required to attain the minimum, median, or maximum volume observed in each site. These total unit costs were then weighted according to the site
volume observed in each scenario:
Minimum monthly volume - Kayunga: 15, Arua: 17, Fort Portal: 8, Luwero: 4, Bwizibwera: 1
Median monthly volume - Kayunga: 109, Arua: 68, Fort Portal: 46, Luwero: 16, Bwizibwera: 9
Maximum monthly volume - Kayunga: 275, Arua: 132, Fort Portal: 83, Luwero: 23, Bwizibwera: 28
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